DOP2012000317A - Compuestos heterociclicos, su preparacion y su aplicacion terapeutica - Google Patents

Compuestos heterociclicos, su preparacion y su aplicacion terapeutica

Info

Publication number
DOP2012000317A
DOP2012000317A DO2012000317A DO2012000317A DOP2012000317A DO P2012000317 A DOP2012000317 A DO P2012000317A DO 2012000317 A DO2012000317 A DO 2012000317A DO 2012000317 A DO2012000317 A DO 2012000317A DO P2012000317 A DOP2012000317 A DO P2012000317A
Authority
DO
Dominican Republic
Prior art keywords
preparation
therapeutic application
compounds
heterociclical
heterociclical compounds
Prior art date
Application number
DO2012000317A
Other languages
English (en)
Inventor
Caroline Leriche
David N Middlemiss
Original Assignee
Fovea Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fovea Pharmaceuticals filed Critical Fovea Pharmaceuticals
Publication of DOP2012000317A publication Critical patent/DOP2012000317A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invencióri está dirigida a determinados compuestos nuevos, a los métodos para producirlos y a tos métodos para tratar o mejorar un trastomo mediado por quinasa.
DO2012000317A 2010-06-22 2012-12-19 Compuestos heterociclicos, su preparacion y su aplicacion terapeutica DOP2012000317A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10305665 2010-06-22

Publications (1)

Publication Number Publication Date
DOP2012000317A true DOP2012000317A (es) 2013-04-15

Family

ID=43033247

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2012000317A DOP2012000317A (es) 2010-06-22 2012-12-19 Compuestos heterociclicos, su preparacion y su aplicacion terapeutica

Country Status (27)

Country Link
US (1) US20130123271A1 (es)
EP (1) EP2585439A1 (es)
JP (1) JP2013533237A (es)
KR (1) KR20130116070A (es)
CN (1) CN103140480A (es)
AR (1) AR081960A1 (es)
AU (1) AU2011268938A1 (es)
BR (1) BR112012032721A2 (es)
CA (1) CA2803496A1 (es)
CL (1) CL2012003637A1 (es)
CO (1) CO6660505A2 (es)
CR (1) CR20120653A (es)
DO (1) DOP2012000317A (es)
EA (1) EA201291329A1 (es)
EC (1) ECSP12012354A (es)
GT (1) GT201200345A (es)
IL (1) IL223721A0 (es)
MA (1) MA34384B1 (es)
MX (1) MX2012015305A (es)
NI (1) NI201200193A (es)
NZ (1) NZ605022A (es)
PE (1) PE20130640A1 (es)
SG (1) SG186424A1 (es)
TN (1) TN2012000610A1 (es)
TW (1) TW201204723A (es)
UY (1) UY33461A (es)
WO (1) WO2011161159A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2343294A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
WO2014195276A1 (en) * 2013-06-07 2014-12-11 Bayer Pharma Aktiengesellschaft Substituted triazolopyridines having activity as mps-1 inhibitors
CA2914668A1 (en) * 2013-06-10 2014-12-18 Volker Schulze Novel compounds for the treatment of cancer
NZ733135A (en) 2014-12-24 2018-06-29 Gilead Sciences Inc Fused pyrimidine compounds for the treatment of hiv
TW202237569A (zh) 2014-12-24 2022-10-01 美商基利科學股份有限公司 喹唑啉化合物
BR112017013440A2 (pt) 2014-12-24 2018-01-09 Gilead Sciences, Inc. compostos de isoquinolina para o tratamento de hiv
US10894784B2 (en) 2015-12-18 2021-01-19 Bayer Pharma Aktiengesellschaft Heteroarylbenzimidazole compounds
US10265315B2 (en) 2016-04-08 2019-04-23 Baylor College Of Medicine Small molecule regulators of steroid receptor coactivators and methods of use thereof
WO2017207534A1 (en) 2016-06-03 2017-12-07 Bayer Pharma Aktiengesellschaft Substituted heteroarylbenzimidazole compounds
WO2021254464A1 (zh) * 2020-06-19 2021-12-23 南京红云生物科技有限公司 取代喹唑啉类化合物、其制备方法、药物组合及应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6056684B2 (ja) 1977-11-07 1985-12-11 東興薬品工業株式会社 点眼剤
US4271143A (en) 1978-01-25 1981-06-02 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
US4407792A (en) 1979-05-09 1983-10-04 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
US4615697A (en) 1983-11-14 1986-10-07 Bio-Mimetics, Inc. Bioadhesive compositions and methods of treatment therewith
US5041434A (en) 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
BR0015718A (pt) 1999-11-22 2002-07-23 Warner Lambert Co Quinazolinas e seu uso para inibição de enzimas de cinase dependente de ciclina
JP2006516561A (ja) 2003-01-17 2006-07-06 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 細胞増殖の阻害剤としての２−アミノピリジン置換ヘテロ環類
JP2007509059A (ja) 2003-10-16 2007-04-12 カイロン コーポレイション 癌の処置のためのＲａｆキナーゼのインヒビターとしての、２，６−二置換キナゾリン、キノキサリン、キノリンおよびイソキノリン
CA2567574C (en) 2004-04-08 2013-01-08 Targegen, Inc. Benzotriazine inhibitors of kinases
NZ553492A (en) 2004-08-25 2010-11-26 Targegen Inc Triazole derivatives and methods of use
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
US20060247250A1 (en) 2005-03-16 2006-11-02 Targegen, Inc. Pyrimidine inhibitors of kinases
EP1878727A4 (en) * 2005-04-28 2013-11-13 Kyowa Hakko Kirin Co Ltd 2-AMINOQUINAZOLINE DERIVATIVES
EP1893216A4 (en) 2005-06-08 2012-08-08 Targegen Inc METHOD AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES
PE20070978A1 (es) 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
WO2008020203A1 (en) 2006-08-17 2008-02-21 Astrazeneca Ab Pyridinylquinaz0linamine derivatives and their use as b-raf inhibitors
TW200829566A (en) 2006-12-08 2008-07-16 Astrazeneca Ab Chemical compounds
KR20090092287A (ko) 2006-12-22 2009-08-31 노파르티스 아게 Ｐｄｋ１ 억제를 위한 퀴나졸린
US20110160232A1 (en) 2007-10-04 2011-06-30 Pingda Ren Certain chemical entities and therapeutic uses thereof
GB0719803D0 (en) * 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
US20100311965A1 (en) 2007-12-28 2010-12-09 Carna Biosciences Inc. 2-aminoquinazoline derivative
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
PE20120424A1 (es) 2008-12-29 2012-05-04 Fovea Pharmaceuticals Compuestos de quinazolina sustituidos
CA2751517A1 (en) * 2009-02-13 2010-08-19 Fovea Pharmaceuticals [1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors

Also Published As

Publication number Publication date
MA34384B1 (fr) 2013-07-03
PE20130640A1 (es) 2013-03-30
CA2803496A1 (en) 2011-12-29
US20130123271A1 (en) 2013-05-16
NZ605022A (en) 2013-12-20
SG186424A1 (en) 2013-01-30
KR20130116070A (ko) 2013-10-22
CL2012003637A1 (es) 2013-07-05
AR081960A1 (es) 2012-10-31
JP2013533237A (ja) 2013-08-22
CO6660505A2 (es) 2013-04-30
EA201291329A1 (ru) 2013-05-30
TW201204723A (en) 2012-02-01
GT201200345A (es) 2014-01-24
TN2012000610A1 (en) 2014-04-01
ECSP12012354A (es) 2013-01-31
WO2011161159A1 (en) 2011-12-29
NI201200193A (es) 2013-05-13
CN103140480A (zh) 2013-06-05
CR20120653A (es) 2013-04-03
UY33461A (es) 2012-01-31
MX2012015305A (es) 2013-05-30
AU2011268938A1 (en) 2013-01-24
BR112012032721A2 (pt) 2016-11-29
IL223721A0 (en) 2013-03-05
EP2585439A1 (en) 2013-05-01

Similar Documents

Publication Publication Date Title
DOP2012000317A (es) Compuestos heterociclicos, su preparacion y su aplicacion terapeutica
LTC2785706I2 (lt) Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
UY33353A (es) Compuestos adecuados para el tratamiento de trastornos metabolicos y metodos de preparacion
CR20140376A (es) Compuestos para tratar la atrofia muscular espinal
CR20150370A (es) Compuestos antivirales
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
CO7111274A2 (es) Moduladores dll3 y métodos de empleo
EA201400178A1 (ru) Лечение рака молочной железы
CO7151485A2 (es) Anticuerpos anti-sez6 y métodos de empleo
TR201910959T4 (tr) Elektromanyetik radyasyonun insan irisine uygulanması.
UY34742A (es) Agentes para tratar trastornos que implican la modulación de receptores de rianodina
BR112013020798A2 (pt) terapia de combinação do inibidor mtor /jak
CL2012003385A1 (es) Tratamiento para la incontinencia.
UY34474A (es) Composiciones, forma de dosificación y métodos para tratar el virus de la hepatitis C.
EA201492040A1 (ru) Бициклически замещённые урацилы и их применение
EA201491610A1 (ru) Модуляторы x рецепторов печени
CO7020867A2 (es) Formulaciones de anticuerpo y metodos
EA201490423A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ, ОТНОСЯЩИЕСЯ К p62, ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ РАКА
EA201400339A1 (ru) Новые имидазоламины в качестве модуляторов киназной активности
MX370253B (es) Composiciones de compuestos de jasmonato y métodos de uso de las mismas.
GT201400242A (es) "nuevos compuestos de pirazol"
BR112014026326A2 (pt) composição para tratamento de distúrbios metabólicos
EA201590656A1 (ru) Азаиндолины